Company Filing History:
Years Active: 2015
Title: Niels Cristoph Riedemann: Innovator in Anti-C5A Therapeutics
Introduction
Niels Cristoph Riedemann is a notable inventor based in Jena, Germany. He has made significant contributions to the field of pharmaceuticals, particularly in the development of binding moieties for therapeutic applications.
Latest Patents
Riedemann holds a patent for "Anti-C5A binding moieties with high blocking activity." This invention relates to binding moieties that specifically target a conformational epitope of C5a, especially human C5a. The preferred binding moieties are anti-C5a antibodies that effectively bind to this epitope. These binding moieties are valuable as active agents in pharmaceutical compositions aimed at treating and preventing various acute and chronic diseases, particularly acute inflammatory diseases such as systemic inflammatory response syndrome (SIRS) and different degrees of sepsis, including sepsis, severe sepsis, and septic shock.
Career Highlights
Riedemann is associated with Inflarx GmbH, where he continues to advance his research and development efforts. His work focuses on innovative solutions for critical health challenges, showcasing his commitment to improving patient outcomes.
Collaborations
Some of his notable coworkers include Renfeng Guo and Yan Li, who contribute to the collaborative efforts at Inflarx GmbH.
Conclusion
Niels Cristoph Riedemann's innovative work in the field of anti-C5A therapeutics highlights his dedication to addressing significant medical challenges. His contributions are paving the way for advancements in the treatment of inflammatory diseases.